Study to Evaluate Safety, Tolerance and Efficacy of ASC22 Combined With ART in Subjects With HIV

NCT05330143 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

19

Enrollment

INDUSTRY

Sponsor class

Conditions

HIV-1-infection
HIV Infections
PD-L1 Gene Mutation

Interventions

DRUG: ASC22 1mg/kg
DRUG: ASC22 2.5mg/kg
DRUG: Antiretroviral Therapy
DRUG: Placebo

Sponsor

Ascletis Pharmaceuticals Co., Ltd.